Regeneron Files Q1 2025 10-Q
Ticker: REGN · Form: 10-Q · Filed: 2025-04-29T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report
TL;DR
Regeneron's Q1 2025 10-Q is in. Financials look solid.
AI Summary
Regeneron Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial figures and business segment performances are presented, reflecting the company's ongoing activities in the pharmaceutical sector.
Why It Matters
This filing provides investors and analysts with the latest financial health and operational details of Regeneron Pharmaceuticals, Inc., crucial for understanding the company's current performance and future outlook.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate red flags.
Key Numbers
- 20250331 — Period End Date (The filing covers financial data up to this date.)
- 2024-12-31 — Previous Period End Date (Comparison point for financial data.)
Key Players & Entities
- REGENERON PHARMACEUTICALS, INC. (company) — Filer
- 0000872589 (company) — Central Index Key
- TARRYTOWN, NY (location) — Business Address
- 20250331 (date) — Period of Report
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, indicating the filing covers the first quarter of 2025.
What is Regeneron Pharmaceuticals, Inc.'s Central Index Key (CIK)?
Regeneron Pharmaceuticals, Inc.'s Central Index Key is 0000872589.
Where is Regeneron Pharmaceuticals, Inc. headquartered?
The company's business address is 777 Old Saw Mill River Road, Tarrytown, NY 10591.
What is the Standard Industrial Classification (SIC) code for Regeneron Pharmaceuticals, Inc.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
When was this 10-Q filing submitted?
This filing was submitted on 20250429.
From the Filing
0001804220-25-000022.txt : 20250429 0001804220-25-000022.hdr.sgml : 20250429 20250429065148 ACCESSION NUMBER: 0001804220-25-000022 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 72 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250429 DATE AS OF CHANGE: 20250429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 25882571 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 10-Q 1 regn-20250331.htm 10-Q regn-20250331 0000872589 12/31 2025 Q1 false 290 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure regn:segment regn:complaint 0000872589 2025-01-01 2025-03-31 0000872589 us-gaap:CommonClassAMember 2025-04-15 0000872589 us-gaap:CommonStockMember 2025-04-15 0000872589 2025-03-31 0000872589 2024-12-31 0000872589 us-gaap:CommonClassAMember 2025-03-31 0000872589 us-gaap:CommonClassAMember 2024-12-31 0000872589 us-gaap:CommonStockMember 2025-03-31 0000872589 us-gaap:CommonStockMember 2024-12-31 0000872589 us-gaap:ProductMember 2025-01-01 2025-03-31 0000872589 us-gaap:ProductMember 2024-01-01 2024-03-31 0000872589 regn:CollaborationRevenueMember 2025-01-01 2025-03-31 0000872589 regn:CollaborationRevenueMember 2024-01-01 2024-03-31 0000872589 us-gaap:ProductAndServiceOtherMember 2025-01-01 2025-03-31 0000872589 us-gaap:ProductAndServiceOtherMember 2024-01-01 2024-03-31 0000872589 2024-01-01 2024-03-31 0000872589 regn:CollaborationandContractManufacturingMember 2025-01-01 2025-03-31 0000872589 regn:CollaborationandContractManufacturingMember 2024-01-01 2024-03-31 0000872589 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2024-12-31 0000872589 us-gaap:CommonStockMember 2024-12-31 0000872589 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000872589 us-gaap:RetainedEarningsMember 2024-12-31 0000872589 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000872589 us-gaap:TreasuryStockCommonMember 2024-12-31 0000872589 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000872589 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000872589 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0000872589 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000872589 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0000872589 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2025-03-31 0000872589 us-gaap:CommonStockMember 2025-03-31 0000872589 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000872589 us-gaap:RetainedEarningsMember 2025-03-31 0000872589 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0000872589 us-gaap:TreasuryStockCommonMember 2025-03-31 0000872589 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-12-31 0000872589 us-gaap:CommonStockMember 2023-12-31 0000872589 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000872589 us-gaap:RetainedEarningsMember 2023-12-31 0000872589 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000872589 us-gaap:TreasuryStockCommonMember 2023-12-31 0000872589 2023-12-31 0000872589 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000872589 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000872589 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000872589 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000872589 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000872589 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2024-03-31 0000872589 us-gaap:CommonStockMember 2024-03-